February 22, 2024Open Access

Supplementary Figure S1 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies

Key Points

Key points are not available for this paper at this time.

Abstract

CD47 gene expression across all of TCGA, shown with a boxplot for each indication (A), and a scatterplot showing the expression of SIRPA compared to the average macrophage gene expression (mean of CD163, CSF1R, CD14 and CD68 gene expression) in TCGA cohorts (B).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Chan et al. (Thu,) studied this question.

synapsesocial.com/papers/68e781eeb6db6435876f4e8e https://doi.org/https://doi.org/10.1158/2767-9764.25266699.v1

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies2024
2Supplementary Figure S2 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies2024
3Supplementary Figure S2 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies2024
4FIGURE 1 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies2024
5FIGURE 3 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies2024

Bookmark

View Full Paper